HomeInvestors & MediaNews
- Exploring various business opportunities based on its 4-1BB based bispecific antibodies and BBB shuttle platforms
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it will attend BIO Europe 2024 to explore various business opportunities.
Bio Europe is the largest bio conference in Europe, with over 2,800 pharmaceutical and bio companies and over 5,500 industry professionals. Bio Europe is held twice a year, in spring and fall, and the fall event that ABL Bio is participating in will be held in Stockholm, Sweden from November 4th to 6th.
At this event, ABL Bio plans to meet with various global pharmaceutical and bio companies to share the latest clinical data of its immuno-oncology pipelines utilizing the 4-1BB-based bispecific antibody platform ‘Grabody-T’. The clinical-stage 4-1BB-based bispecific antibodies of ABL Bio are ABL503/ragistomig, ABL111/givastomig, and ABL103, all of which are in the Phase 1 clinical stage. ABL503/ragistomig presented the interim results of a Phase 1 clinical trial for monotherapy at the American Society of Clinical Oncology (ASCO) this year, and ABL111/givastomig additionally disclosed the results of a Phase 1 clinical trial for monotherapy at the recent European Society for Medical Oncology (ESMO). ABL103 is currently undergoing a Phase 1 dose escalation part in Korea.
ABL Bio will also have a meeting to discuss on its Blood Brain Barrier (BBB) shuttle platform, 'Grabody-B'. As interest in BBB shuttle is increasing globally, ABL Bio expects that there will be many meaningful meetings at this event.
Sang Hoon Lee, CEO of ABL Bio said "starting with the J.P. Morgan Healthcare Conference early this year, we have been continuing meeting with global pharmaceutical and bio companies at events including BIO USA and BIO Europe to share the latest clinical data. In addition to the development of existing pipelines, ABL Bio is also focusing on the development of bispecific ADCs (Antibody Drug Conjugate). We plan to do our best to communicate with various industry players around the world to understand the trends and not miss any business opportunities."
Meanwhile, ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. ABL’s lead program, ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. The program recently completed patient enrollment in a Phase 2/3 clinical trial for biliary tract cancer and the top-line data will be disclosed in 2025. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).
Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.